Radiation plus immunotherapy for recurrent rectal cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests whether giving targeted radiation and an immunotherapy drug together can control locally recurring rectal cancer in the pelvis. It may help shrink tumors and slow disease growth, especially after certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old when you sign consent
- Your overall health is good enough for treatment (doctor-rated “ECOG 0–1”)
- Your scan shows a pelvic recurrence of rectal cancer with at least one measurable tumor, and limited spread (no more than 5 distant lesions in up to 3 organs)
- You have not had radiation to the pelvic area within the last 6 months
- Your blood counts and organ tests (bone marrow, liver, kidneys, and clotting) are adequate based on labs from within 7 days before treatment
- Your doctor believes you can live at least 24 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining standard chemoradiation with an immunotherapy drug (toripalimab) before surgery for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help remove the tumor more effectively.
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This study tests whether combining immunotherapy with a short course of radiation given before surgery can improve outcomes in early-stage rectal cancer. It may help the immune system work better against the tumor before it is removed.
Hear when a new Recurrent Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.